Topic Review
Therapeutic Potential of Fungal Terpenes and Terpenoids
Terpenes and their derivatives comprise a diverse group of natural compounds with versatile medicinal properties. This article elucidates the general characteristics of fungal terpenes and terpenoids, encompassing their structure and biogenesis. The focal point of this work involves a comprehensive overview of these compounds, highlighting their therapeutic properties, mechanisms of action, and potential applications in treating specific skin conditions. Numerous isolated terpenes and terpenoids have demonstrated noteworthy anti-inflammatory and anti-microbial effects, rivalling or surpassing the efficacy of currently employed treatments for inflammation or skin infections. Due to their well-documented antioxidant and anti-cancer attributes, these compounds exhibit promise in both preventing and treating skin cancer. Terpenes and terpenoids sourced from fungi display the capability to inhibit tyrosinase, suggesting potential applications in addressing skin pigmentation disorders and cancers linked to melanogenesis dysfunctions.
  • 56
  • 15 Apr 2024
Topic Review
Cyclodextrin-Based Drug Delivery Systems
Cyclodextrin-based nanosponges (CDNSs) are complex macromolecular structures composed of individual cyclodextrins (CDs) and nanochannels created between cross-linked CD units and cross-linkers.
  • 45
  • 01 Apr 2024
Topic Review
URAT1 and Other UA Transporters with Metabolic Syndrome
Urate transporter 1 (URAT1), which is a urate anion exchanger that regulates serum uric acid (UA) levels in the human kidney, was identified in 2002, and it has been targeted by uricosuric agents. In humans, renal reabsorption of UA into the blood plays an important role in controlling serum UA levels. The UA exchange is mediated by various molecules expressed in the renal proximal tubule. UA enters the proximal tubule epithelial cells in exchange for monocarboxylate via apical URAT1 and for dicarboxylate via the apical organic anion transporter (OAT) 4. OAT1 and OAT3 on the basolateral membrane of epithelial cells transport UA from the renal interstitial into the renal proximal tubule epithelial cells. Renal UA reabsorption is mainly mediated by URAT1 and glucose transporter 9 (GLUT9). Apical GLUT9b plays a significant role in UA reabsorption; the reabsorbed UA exits the proximal tubule epithelial cells into the blood through basolateral GLUT9a. The ATP-binding cassette transporter G2 (ABCG2) has been identified as a high-capacity UA exporter that mediates renal and/or extra-renal (intestinal) UA excretion.
  • 88
  • 27 Mar 2024
Topic Review
Four Atraphaxis Species
Atraphaxis is a genus of flowering plants in the family Polygonaceae, with approximately 60 species. Species of Atraphaxis are much-branched woody plants, forming shrubs or shrubby tufts, primarily inhabiting arid zones across the temperate steppe and desert regions of Central Asia, America, and Australia. Atraphaxis species have been used by diverse groups of people all over the world for the treatment of various diseases.
  • 59
  • 26 Mar 2024
Topic Review
Opioid-Induced Constipation in Cancer Patients
Opioid-induced constipation (OIC) is a disabling symptom which 60–90 percent of cancer patients with chronic opioid use experience. Peripherally acting μ-opioid receptor antagonists (PAMORAs) are a class of medications aiming to reverse opioids’ adverse effects on the gut by interacting with opioid receptors in the gastrointestinal tract without significantly crossing the blood–brain barrier, and therefore they are not affecting the analgesic opioid effects in the central nervous system.
  • 45
  • 22 Mar 2024
Topic Review
Flavonoids as CYP3A4 Inhibitors In Vitro
CYP enzymes are a group of heme-containing enzymes that play important roles in the metabolism of many drugs and other xenobiotics. They are located in the endoplasmic reticulum of cells throughout the body, but they are most abundant in the liver.
  • 54
  • 22 Mar 2024
Topic Review
Anticancer Effects of α-Linolenic Acid
α-linolenic acid (ALA) belongs to the family of n-3 polyunsaturated fatty acids (n-3 PUFAs) and contains a carbon–carbon double bond on the third carbon atom at the methyl end of the carbon chain. This family of essential fatty acids also includes eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). ALA has gradually attracted increased attention due to its nutritional and medicinal advantages. Studies have shown that ALA exerts beneficial effects on a variety of diseases, including cancer.
  • 56
  • 19 Mar 2024
Topic Review
Extracellular Vesicles-Loaded Microneedle Technology
Microneedles (MNs), renowned for their painless and minimally invasive qualities, exhibit significant potential for facilitating effective drug delivery, vaccination, and targeted sample extraction. Extracellular vesicles (EVs), serving as cargo for MNs, are naturally occurring nanovesicles secreted by cells and characterized by novel biomarkers, low immunogenicity, and cell-source-specific traits. MNs prove instrumental in extracting EVs from the sample fluid, thereby facilitating a promising diagnostic and prognostic tool. To harness the therapeutic potential of EVs in tissue repair, MNs with sustained delivery of EVs leverage micron-sized channels to enhance targeted site concentration, demonstrating efficacy in treating various diseases, such as Achillea tendinopathy, hair loss, spinal cord injury, and diabetic ulcers. EV-loaded MNs emerge as a promising platform for repair applications of skin, cardiac, tendon, hair, and spinal cord tissues.
  • 289
  • 18 Mar 2024
Topic Review
Cultivation and Pharmacological Activities of Taxus mairei
Taxus mairei (Lemée and H.Lév.) S.Y.Hu, indigenous to the southern regions of China, is an evergreen tree belonging to the genus Taxus of the Taxaceae family. Owing to its content of various bioactive compounds, it exhibits multiple pharmacological activities and has been widely applied in clinical medicine.
  • 54
  • 14 Mar 2024
Topic Review
Polypharmacy in Older Patients with COVID-19
Polypharmacy is the use of multiple and potentially inappropriate medications (PIMs) that lack sufficient evidence of benefits and/or increase the risks of adverse drug reactions. It is an increasing problem among older adults. The global polypharmacy prevalence is 34.6% in patients with COVID-19, and polypharmacy in COVID-19 increases with age. 
  • 48
  • 14 Mar 2024
  • Page
  • of
  • 106